Xentria, Inc.
🇺🇸United States
Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS Glargine (G), United States (US)-Lantus®, and European Union (EU)-Lantus®
Phase 1
Recruiting
- Conditions
- Healthy Participants
- Interventions
- Drug: US-Lantus®Drug: EU-Lantus®Drug: NKF-INS(G)
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Xentria, Inc.
- Target Recruit Count
- 114
- Registration Number
- NCT06627478
- Locations
- 🇿🇦
FARMOVS Clinical Research Organisation, Bloemfontein, South Africa
Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia®
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Xentria, Inc.
- Target Recruit Count
- 440
- Registration Number
- NCT06504966
Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(A), US-NovoLog®, and EU-NovoRapid®
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- Drug: NKF-INS(A)Drug: EU-NovoRapid®Drug: US-NovoLog®
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Xentria, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT06492226
- Locations
- 🇿🇦
Xentria Investigative Site, Bloemfontein, South Africa
Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia®
Phase 1
Recruiting
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Xentria, Inc.
- Target Recruit Count
- 225
- Registration Number
- NCT06310824
- Locations
- 🇳🇱
Xentria Investigative Site, Groningen, Netherlands
An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Xentria, Inc.
- Target Recruit Count
- 94
- Registration Number
- NCT06169397
- Locations
- 🇬🇧
Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, England, United Kingdom
🇺🇸Xentria Investigative Site, Philadelphia, Pennsylvania, United States
🇬🇧King's College Hospital NHS Foundation Trust, London, England, United Kingdom
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Xentria, Inc.
- Target Recruit Count
- 94
- Registration Number
- NCT05890729
- Locations
- 🇪🇸
Xentria Investigative Site, Sevilla, Spain
🇬🇧University Hospitals Coventry and Warwickshire NHS Trust, Coventry, England, United Kingdom
🇬🇧University College London Hospitals NHS Foundation Trust, London, England, United Kingdom
Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Infusion of XTMAB-16 in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Xentria, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04971395
- Locations
- 🇺🇸
MedStar Harbor Hospital, Baltimore, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath